Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BIND Therapeutics, a US-based clinical-stage nanomedicine platform company, has entered into a research agreement with Roche to discover new nanomedicines using Accurins to treat diseases in therapeutic areas outside of oncology.
Subscribe to our email newsletter
The partnership will focus on combining BIND’s Accurin technology with Roche’s proprietary therapeutic payloads and targeting ligands.
BIND Therapeutics chief executive officer Scott Minick said the addition of Roche to the company’s family of collaborators underscores its position in the field of nanomedicine.
"By combining BIND’s Medicinal Nanoengineering platform with Roche’s deep expertise in disease areas with high unmet medical need, this agreement further validates the wide-ranging potential for our technology and facilitates extending our platform into new therapeutic areas," Minick said.
BIND plans to leverage its Medicinal Nanoengineering platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical firms.
The company’s lead drug candidate, BIND-014, is an Accurin that targets PSMA and includes docetaxel, a clinically-validated and widely used cancer chemotherapy drug.
Currently, BIND-014 is in Phase II clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer.